Objectives This study assessed prevalence and correlates of anergy among a cohort of drug users in communities in the San Juan metropolitan area.
At the beginning of this century, tuberculosis mortality in Puerto Rico reached the rate of 300 deaths per 100 000 population. Tuberculosis mortality rates have continuously declined since 1933 to 33 per 100 000 population in 1955 and 2.5 in 1986. Similarly, the tuberculosis incidence rate in 1970 was 29.1 per 100 000 population, decreasing by 1978 to 13.8. However, an aggressive search for new cases by the Tuberculosis Surveillance Program of the Puerto Rico Health Department in 1979 uncovered a substantially higher rate of 21.9 . With the return of routine surveillance in 1990, the rate declined to 7.9. The difference between aggressive and passive monitoring of tuberculosis has led public health officials to conclude that routine surveillance does not reflect the true incidence of this disease in Puerto Rico. Substantial underreporting by health systems and professionals is suspected. 1 The introduction of the human immunodeficiency virus (HIV) into populations with high prevalence of tuberculosis has resulted in a severe setback to worldwide tuberculosis control. The increase in tuberculosis has been attributed to the concurrent rise in the HIV incidence. Recent studies show that active tuberculosis not only is an independent marker of advanced immunosuppression in HIV-infected patients, but also appears to act as a cofactor in the acceleration of the clinical course of HIV. 2 Most HIV infected patients who have developed AIDS or who are at advanced stages of immunosuppression are anergic on multiple skin testing. Consequently, latent tuberculosis infection may not be detected. 3 Previous studies report a high incidence (12.4%) of tuberculosis among HIV infected patients in Spain who are anergic on multiple skin tests. 4 Studies in the US show 27% anergy prevalence rate among seropositive subjects in a cohort of drug users in New York City. 5 In previous studies, we reported HIV prevalence rates between 35% and 45% among drug users not in treatment. 6, 7 Moreover, we found that 45% of HIV seropositive drug users and 22% of seronegative drug users were anergic. Given the magnitude of both HIV and anergy among drug users in Puerto Rico, 6 especially when compared to other areas, 4, 5, 8 the present investigation was initiated. Its purpose was to assess factors associated with anergy among seropositive and seronegative drug users recruited in communities of the San Juan metropolitan area.
The study subjects, 719 drug injectors and crack users, were recruited between March 1994 and February 1995, following a stratified cluster design of 34 copping areas (street settings where illicit drugs are sold). Using a three-stage probability protocol, crack and injection drug users buying drugs at copping areas in the San Juan metropolitan area were selected for recruitment. Each month, a fixed number of copping areas and recruitment days and times were selected at random. On the designated day and time, outreach workers visited selected copping areas and estimated the number of buyers in the area. A buyer was then selected at random using standard Kish selection tables. The selected individual was invited to participate and a written appointment was made. Outreach workers followed-up and encouraged participation from the selected users for up to 30 days. Eligibility criteria included: (1) age Ͼ17 years; (2) self-reported use of heroin, cocaine/crack within the previous 30 days; (3) no treatment for substance abuse within the previous 30 days; (4) verification of drug use through visual inspection for signs of recent venipuncture and urinalysis for morphine as well as cocaine; and, (5) not too intoxicated or otherwise dysfunctional to respond to questions.
On the first visit to the programme's assessment centre, patients were asked to provide informed consent for the tests and the interview portion of the study. On-site interviews were conducted by a trained research assistant with extensive experience conducting interviews with drug users. The Risk Behavior Assessment (RBA), developed by the National Institute on Drug Abuse and translated into Spanish, served to assess demographics, drug use patterns, needle and sex risk behaviours, incarceration history, health status, and health care and drug treatment programme utilization. Reliability and validity tests of the RBA have shown it to be suitable for studies with this population. 12 Respondents were also assessed using a second short questionnaire to identify factors related to the risk of tuberculosis infection. This instrument was developed in consultation with pneumologists and infectious disease specialists at the Department of Internal Medicine of the School of Medicine of the Universidad Central del Caribe. It assessed individual and family history of tuberculosis, tuberculosis symptomatology, access to tuberculosis clinics, and tuberculosis treatment.
On the first visit, all subjects without a documented history of a tuberculin skin test or a previous tuberculosis diagnosis were also administered a purified protein derivative (PPD) skin test and an anergy panel. Skin test responses are used to measure immunological competence. It is recommended and necessary to use antigens to which the subjects under study are expected to be sensitized; 13 an antigen's response will vary somewhat according to geographical area and characteristics of patient population. 14 This investigation was the first anergy study conducted in Puerto Rico among drug users. Since data were not collected from the general population, nor from specific groups of patients in the health care system, there was no information available on the types of antigens most appropriate for use with this population. In the first phase of the project, we used intradermal application of tuberculin, mumps, and tetanus to test for anergy. In order to corroborate prevalence rates observed from these antigens, Candida was added to the protocol for the last 150 subjects tested. In the absence of any difference in rate of anergy between the groups before and after Candida was added, the groups were combined for subsequent analyses.
Subjects were asked to return in 2 days for the reading of the skin test. Anergy was defined as having an induration of Ͻ2 mm at 48 h.
Blood samples for HIV testing were also taken from subjects on their first visit. The HIV serostatus was determined using standard ELISA (enzyme-linked immunoabsorbent assay) techniques with confirmation by Western Blot (DuPont Company, Wilmington, DE). Two weeks following the HIV test, study participants returned to receive HIV post-test counselling and test results, and referrals to appropriate health care and social service agencies were provided. Subjects testing positive to the HIV test had another blood sample drawn for CD4+ cell counts. The CD4+ cell counts were measured by flow cytometry. Due to unanticipated logistical problems with the laboratory, we were able to process 68.1% of the specimens collected. The PPD and anergic HIV positive subjects were referred to tuberculosis clinics for further diagnostic tests and, if recommended, for treatment. All study procedures were approved by the Institutional Review Board of the School of Medicine of the Universidad Central del Caribe in Bayamón, Puerto Rico. Participants were compensated $20 for their time as research participants.
Statistical analysis
Descriptive analyses were used to characterize the study sample. All independent variables (employment status, homelessness, incarceration, crack use, physical incapacity, and chronic illness) were dichotomized. Chi-square tests for proportions were used to assess bivariate association between anergy and sociodemographics, drug use history and health-related variables. When cell sizes in a contingency analysis table were small, exact P-values were calculated using StatXact software (CYTEL, 1998). Comparisons of HIV serostatus and antigen reactivity were made using odd ratios (OR) and 95% confidence intervals (CI). Multiple logistic regression was used to calculate adjusted OR and 95% CI. All analyses were performed with SPSS for Windows, version 7.0 (SPSS, 1997).
Results
Of the 719 subjects recruited, 650 (90.4%) returned to the assessment centre for skin test reading and have been included in this study. Prior to analysing factors associated with anergy, we first compared those who returned for their skin test readings and those who did not, and failed to detect any significant difference in terms of sociodemographic characteristics and years of drug injection. Participants were predominantly male (77.1%); slightly more than half (50.5%) were 25-34 years of age; nearly two-thirds (62.2%) had completed Ͻ12 years of education; half (50.5%) reported crack use, and nearly threequarters (73.5%) reported drug injection. A substantial proportion (34.2%) were HIV-positive and anergic (30.3%). Tuberculin skin test results show 8.3% tested positive for tuberculosis infection ( Table 1) . Table 2 summarizes the results of the analysis of variables associated with anergy, controlling for sociodemographic characteristics. Subjects with an incarceration history were one-and-a-half times more likely to be anergic than those not reporting previous incarceration. Crack users were 1.6 times more likely to be anergic than those not reporting crack use. The HIV seropositive subjects were three times more likely to be anergic than seronegatives. Subjects who reported a chronic illness were nearly two times more likely to be anergic than those not reporting a chronic illness. Table 3 shows the results of the bivariate association between skin test and serological status. Subjects who tested seropositive for HIV were nearly three times more likely to be anergic than those who were seronegative. This effect was observed for mumps and tetanus but not for Candida. Moreover, no significant differences were observed between groups in the response to the PPD skin test.
Measures of CD4+ cell counts were available from 147 of the 216 (68.1%) HIV seropositive subjects. With these data, we tested the association of anergy with CD4+ cell counts. The HIV seropositive individuals with CD4+ cell counts Ͻ200/mm 3 were more likely to be anergic than HIV seropositive subjects with CD4+ cell counts of у200/mm 3 (65.0% versus 37.7%, respectively, P = 0.022).
Discussion
Little is known and many questions are still unanswered about the effect of geographical location on the frequency of skin test reactions to given antigens. 15 Without previous research on anergy among groups of the Puerto Rican population, particularly drug users, we defined anergy as no reaction to the four antigens widely employed in previous studies to assess delayed hypersensitivity. 4, 5, 8 Individuals reactive to one test were usually reactive to others. Reactions to mumps and tetanus were associated with HIV seropositivity, although this was not the case with Candida. As expected, CD4+ cell counts were associated with anergy status among HIV seropositive subjects.
Overall, 197 (30%) of our study subjects showed no skin reactivity to the antigens and were thus determined to be anergic. Other community studies with similar populations of drug users have reported anergy rates of 18%. 8 Population-based surveys suggest that less than 5% of healthy individuals screened using four antigens will be anergic. Studies among homosexual men in Baltimore, a population at risk of HIV infection and also at risk of tuberculosis, show a 12% prevalence of anergy. 16 Thus, the sample population of drug users in Puerto Rico had a notably higher than expected prevalence of anergy. Anergy is almost universal in patients with AIDS, but its prevalence in asymptomatic individuals with HIV antibodies is less defined. In our study, 45.5% of the HIV seropositive subjects, and 22.2% of the seronegative subjects, were anergic.
In this study, increasing age, as well as certain underlying medical conditions were hypothesized to be associated with anergy. In fact, age proved not to be associated with anergy, while chronic illness was significantly related to this health condition. With continuous exposures to multiple health risks and their consequences, such as homelessness, life strains and stressors, inadequate diet and patterns of health care, poor health status in this population is to be expected. Further studies are needed to detect the health conditions that specifically affect anergy. Other variables, such as incarceration history and crack use, were associated with anergy. Data from recent studies of this group of researchers show incarceration history to be significantly associated with HIV seropositivity among drug users. Studies in other countries also demonstrate the high health risks associated with jail and prison environments. [17] [18] [19] [20] Anergy status among drug users needs to be further studied. Information is needed to understand the effects of the characteristics of the drugs used (purity, quantity), their method of utilization, the characteristics and lifestyles of the individuals who use specific drugs, and the frequency of drug use, on anergy status, particularly among drug injectors. These behaviours have been found to be associated with various diseases and health conditions. 6, 10, 21 For example, Mientjes et al. 15 report that lymphocyte reactivity is depressed by frequent drug injection in HIV seropositive and seronegative drug users. More studies will also be needed to detect the accuracy of anergy tests in different populations and geographical areas.
The findings of this study should be considered in view of a number of limitations. It was not possible to select a probability sample and the findings may thus lack generalizability to other drug users in the area. However, we have attempted to reduce self-selection biases and increase representativeness by selecting our subjects from predefined catchment areas and by sampling from copping sites. A further methodological concern is the validity of self-reporting of some measures (i.e. incarceration history, number of chronic illnesses, etc.). However, a number of studies tend to indicate that drug users' response to surveys, such as that reported here, are reasonably accurate for research purposes. 12, 22 ANERGY AND DRUG USE IN PUERTO RICO 511 Although controversy continues related to the accuracy of anergy testing in different geographical sites and populations, anergy tests that are currently available should be administered to groups at high risk of HIV infection, such as drug users. 
